Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.
Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C. Van Der Steen N, et al. Clin Lung Cancer. 2018 Jan;19(1):35-41. doi: 10.1016/j.cllc.2017.06.010. Epub 2017 Jul 6. Clin Lung Cancer. 2018. PMID: 28757336 Review.
cMET Exon 14 Skipping: From the Structure to the Clinic.
Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. Van Der Steen N, et al. J Thorac Oncol. 2016 Sep;11(9):1423-32. doi: 10.1016/j.jtho.2016.05.005. Epub 2016 May 17. J Thorac Oncol. 2016. PMID: 27223456 Free article. Review.
Onartuzumab in lung cancer: the fall of Icarus?
Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Rolfo C, et al. Among authors: van der steen n. Expert Rev Anticancer Ther. 2015 May;15(5):487-9. doi: 10.1586/14737140.2015.1031219. Epub 2015 Mar 30. Expert Rev Anticancer Ther. 2015. PMID: 25818471
APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Deben C, Lardon F, Wouters A, Op de Beeck K, Van den Bossche J, Jacobs J, Van Der Steen N, Peeters M, Rolfo C, Deschoolmeester V, Pauwels P. Deben C, et al. Among authors: van den bossche j, van der steen n. Cancer Lett. 2016 Jun 1;375(2):313-322. doi: 10.1016/j.canlet.2016.03.017. Epub 2016 Mar 11. Cancer Lett. 2016. PMID: 26975633
FGFR a promising druggable target in cancer: Molecular biology and new drugs.
Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C. Porta R, et al. Among authors: van der steen n. Crit Rev Oncol Hematol. 2017 May;113:256-267. doi: 10.1016/j.critrevonc.2017.02.018. Epub 2017 Mar 23. Crit Rev Oncol Hematol. 2017. PMID: 28427515 Review.
Resistance Mechanisms to AZD9291 and Rociletinib-Letter.
Van Der Steen N, Rolfo C, Pauwels P, de Langen AJ, Peters GJ, Giovannetti E. Van Der Steen N, et al. Clin Cancer Res. 2017 Jul 15;23(14):3966. doi: 10.1158/1078-0432.CCR-17-0167. Clin Cancer Res. 2017. PMID: 28710317 No abstract available.
30 results